Novotech secures regional ‘Best Biologics CRO’ award

Asia Pacific-based Novotech, which recently expanded its services to the US, has been awarded the Best Biologics CRO [clinical research organisation] Award.

The award was presented at a ceremony as part of the 11th Biologics Manufacturing Korea, the 6th Cell and Gene Therapy World East Asia and the 3rd BioLogistics World Korea conferences (29th – 30th June 2022).

The ceremony attracted more than 300 representatives from Korea’s top biopharmaceutical companies, vaccine manufacturers and biologics companies.

Novotech country managing director Sanghee Kim said the Korea team was extremely pleased to receive this award in recognition of the clinical excellence provided to clients in the biologics sector.

The company’s vice president and global head of clinical services Yooni Kim added, “Novotech’s Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.”

Novotech now has a workforce of around 2,500 clinical trial professionals across Australia, New Zealand, South Korea, Greater China, Southeast Asia, India, South Africa and the US.

Novotech CEO Dr John Moller said: “The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest-growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms have accelerated approval processes.

“The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs. Clients will receive a seamless service, with a unified approach to systems and SOPs.”

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.